Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation

Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakızcı Uyar, Bahar, Ensarioğlu, Kerem, Kurt, E. Bahar, Özkan, Derya, Özbal Güneş, Serra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish Society of Anaesthesiology and Reanimation 2022
Materias:
Case Report Intensive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361135/
https://www.ncbi.nlm.nih.gov/pubmed/35801331
http://dx.doi.org/10.5152/TJAR.2021.20450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361135/
https://www.ncbi.nlm.nih.gov/pubmed/35801331
http://dx.doi.org/10.5152/TJAR.2021.20450

Ejemplares similares